System Labs Review

What the July 2026 FDA panel did and did not do

A lot of peptide marketing has leaned on this, so be precise. On 23–24 July 2026 the FDA's Pharmacy Compounding Advisory Committee recommended adding six peptides — BPC-157, KPV, TB-500, MOTS-c, epitalon and semax — to the 503A bulk drug substances list, and voted against emideltide. FDA's own scientists had recommended against all seven on the grounds of limited safety and effectiveness evidence. The committee only advises; the list does not change until formal rulemaking, and every one of those substances remains an unapproved drug today. Crucially, none of the therapies System Labs sells were in that vote. Nothing that happened in July made sermorelin, NAD+ or glutathione any more approved than they were before.

Why the pharmacy matters more than usual

With unapproved compounded injectables, sourcing is the main safety variable. In February 2019 the FDA warned compounders not to use a dietary-supplement-grade L-glutathione powder for sterile injectables after seven patients suffered adverse events consistent with excessive endotoxin. Separately, in 2026 a woman in New York died following an NAD+ injection at a Bronx wellness centre, given by a man accused of practising medicine without a licence. Neither event involves System Labs, and the second is really a story about unlicensed practice rather than the compound. They are cited here because they define the risk profile of the category: who compounds it, and who injects it, matters more than the name on the vial. System naming The Pharmacy Hub is a point in its favour — ask for potency and sterility documentation anyway.

There is a prescription estrogen in the skin cream

System lists the GHK-Cu 'renewal cream' as estriol 0.3%, niacinamide 3%, GHK-Cu 0.2% and hyaluronic acid 0.5%. Three of those are routine skincare actives. Estriol is a hormone. It is the weakest human estrogen and topical use on a small area such as the face has generally not been shown to shift systemic levels meaningfully, so this is a flag rather than an alarm — but it means the product is a prescription medicine and should not be treated as a moisturiser. It is not appropriate in pregnancy or breastfeeding, and anyone with a history of estrogen-receptor-positive breast cancer, unexplained vaginal bleeding or another hormone-sensitive condition should not use it without clearance from their physician or oncologist.

What to check before you buy

• •Budget on the ongoing price, not the first-month price — the gap is roughly 2x across the range
• •Ask which pharmacy fills your specific order and request potency and sterility documentation
• •Confirm the cost of the Rythm blood panel — you get 20% off it, not the panel itself
• •For the GLP-1 product, confirm in writing which molecule and dose you are being prescribed
• •Check your clinician's licence on your state medical board — System says details are in the portal
• •Remember refunds stop once a prescription is ordered, and cancellation is currently by email only

What does System Labs cost?

Every product is sold as a monthly subscription with a discounted first month, and the gap between the two is large. Checked on 7 August 2026, the published rates were: compounded GLP-1/GIP $99 first month then $179/month; NAD+ injection $89 then $149; NAD+ nasal spray $69 then $119; glutathione injection $79 then $149; sermorelin injection $109 then $219; oral sermorelin $79 then $159; MIC+B12 $89/month; and the GHK-Cu topical cream $109/month. Bundles are also offered — the Longevity Stack combining sermorelin, NAD+ and glutathione was $249 for the first month and $517/month thereafter. Injection supplies and two-day shipping are included. Blood testing is not: plans carry a 20% discount on a third-party Rythm panel, so budget separately for that.

Is any of this FDA-approved?

No, and to its credit System Labs says so itself on every product page: 'The peptide medications and therapies offered have not been approved by the FDA. The FDA has not evaluated statements regarding benefits of these therapies. These products are not intended to diagnose, treat, cure, or prevent any disease.' That is the single most important sentence on the site. Compounded medications are prepared by licensed pharmacies for patient-specific prescriptions; they are not reviewed by the FDA for safety, effectiveness or quality. Sermorelin is a particular case — it held FDA approval as Geref for growth hormone deficiency in children, but was withdrawn from the market in 2008 for commercial reasons and is now available only as a compounded preparation. It has never been approved for anti-ageing, athletic performance or body composition in healthy adults.

Did the FDA just approve peptides for compounding?

No, and this is worth getting right because a lot of marketing has blurred it. On 23–24 July 2026 the FDA's Pharmacy Compounding Advisory Committee voted to recommend adding six peptides — BPC-157, KPV, TB-500, MOTS-c, epitalon and semax — to the 503A bulk drug substances list, and voted against a seventh, emideltide. FDA's own scientists had recommended against all seven, citing limited evidence of safety and effectiveness. Two things follow. First, the committee only advises: the list is unchanged until formal rulemaking, and all of those substances remain unapproved drugs. Second, none of the products System Labs actually sells were part of that vote. A committee recommendation about different peptides is not FDA endorsement of sermorelin, NAD+ or glutathione.

How safe are injectable NAD+ and glutathione?

The honest answer is that the risk sits mostly in sourcing and administration rather than in the molecules being exotic. Two documented episodes are worth knowing. In February 2019 the FDA warned compounders not to use a dietary-supplement-grade L-glutathione powder to make sterile injectables after seven patients suffered adverse events consistent with high endotoxin levels. And in 2026 a woman in New York died after an NAD+ injection at a Bronx wellness centre, administered by a man accused of practising medicine without a licence. Neither incident involves System Labs, and the second is fundamentally a case about unlicensed practice. But both illustrate why the pharmacy behind the vial and the clinician behind the prescription matter more here than in approved-drug medicine. Ask System which pharmacy is filling your order and ask to see potency and sterility documentation.

Does System Labs prescribe semaglutide or tirzepatide?

It offers a compounded GLP-1/GIP product at $99 for the first month and $179/month thereafter, with injection supplies and shipping included. The lander does not name semaglutide or tirzepatide explicitly in the material we reviewed, so confirm exactly which molecule and dose you are being prescribed before paying. As with everything else on the platform, it is compounded and therefore not FDA-approved and not equivalent to Ozempic, Wegovy, Mounjaro or Zepbound beyond a shared active ingredient. If a GLP-1 is your main objective, the dedicated providers reviewed on this site are generally cheaper and have far longer track records.

What is in the GHK-Cu cream, and is it just a cosmetic?

It is not just a cosmetic, and this deserves attention. System lists the formulation as estriol 0.3%, niacinamide 3%, GHK-Cu 0.2% and hyaluronic acid 0.5%. Niacinamide, GHK-Cu and hyaluronic acid are ordinary skincare actives. Estriol is not — it is an estrogen, and a prescription hormone. Estriol is the weakest of the human estrogens and topical application to a small area such as the face has generally not been shown to move systemic hormone levels meaningfully, so this is not an alarm. But it does mean the product should be treated as a prescription medicine: it is not appropriate in pregnancy or breastfeeding, and anyone with a history of estrogen-receptor-positive breast cancer, unexplained vaginal bleeding or another hormone-sensitive condition should not use it without their oncologist's or physician's clearance. Compounded hormone creams also lack the standardised absorption testing required of approved products.

Can I get a refund or cancel?

Cancellation is straightforward in principle but manual in practice: System says to email support@systemlabs.com, and notes that a self-service billing portal is 'coming soon'. Refunds are considerably tighter. The company states it 'cannot offer refunds for services already rendered or prescriptions that were ordered', and that prescription medications cannot be returned once dispensed under pharmacy regulations. If you have paid for something not yet delivered you can request a refund and System says it will review it. In practice, treat your money as committed from the moment the prescription goes to the pharmacy.

Where is it available, and who should not use these products?

System Labs states it is available in all 50 US states, with actual treatment availability depending on state telehealth regulations and pharmacy licensing — so confirm your own state during intake. It is a United States service. On who should not use these products: because none of them are FDA-approved, there is no approved labelling setting out contraindications, which is itself a reason for caution. Do not start peptide or hormone therapy while pregnant, trying to conceive or breastfeeding. Anyone with an active or past cancer — particularly hormone-sensitive cancer — should not begin growth-hormone-axis therapy such as sermorelin without specialist advice, as GH and IGF-1 signalling is a genuine concern in that setting. People with diabetes, thyroid disease, kidney or liver impairment, or who take multiple prescription medicines should review the whole plan with their own physician. This page is information, not medical advice.

Is System Labs legitimate?

It looks like a real, funded business rather than a grey-market peptide seller — but it is very new and there is almost nothing independent to check it against. System Laboratories Inc. is based in San Francisco, is venture-backed, names The Pharmacy Hub in Miami as its primary compounding partner, publishes prices openly and states plainly that its products are not FDA-approved. All of that is better disclosure than much of this category offers. Against it: the company was founded in 2026, and we could not locate a Trustpilot profile, a BBB file, or any meaningful volume of independent customer reviews. Individual clinicians are not named publicly. That is not evidence of a problem; it is an absence of evidence either way, and you should price that uncertainty in before prepaying for a stack.